{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:08:31Z","timestamp":1758845311023,"version":"3.44.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018636","name":"Xuzhou Science and Technology Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018636","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.intimp.2025.115406","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:52:36Z","timestamp":1756295556000},"page":"115406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The role and mechanism of PAK5 in the development and immunotherapy of oral squamous cell carcinoma"],"prefix":"10.1016","volume":"164","author":[{"given":"Yuchen","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Mou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiadong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunru","family":"Leng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yameng","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115406_bb0005","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.4317\/medoral.18772","article-title":"Oral cancer: current role of radiotherapy and chemotherapy","volume":"18","author":"Huang","year":"2013","journal-title":"Med. Oral Patol. Oral Cir. Bucal."},{"key":"10.1016\/j.intimp.2025.115406_bb0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e18086","article-title":"A novel method of intra-arterial chemotherapy for oral cancer","volume":"36","author":"Ohmae","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115406_bb0015","doi-asserted-by":"crossref","first-page":"41127","DOI":"10.1021\/acsami.0c12734","article-title":"Highly enhanced antitumor immunity by a three-barreled strategy of the l-arginine-promoted nanovaccine and gene-mediated PD-L1 blockade","volume":"12","author":"Hu","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.intimp.2025.115406_bb0020","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.115406_bb0025","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2025.115406_bb0030","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41401-020-00570-8","article-title":"Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan\/JQ1 for chemo-immunotherapy","volume":"42","author":"He","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.intimp.2025.115406_bb0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115406_bb0040","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2025.115406_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115406_bb0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2025.115406_bb0055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/jclinpath-2017-204853","article-title":"PD-L1","volume":"71","author":"Kythreotou","year":"2018","journal-title":"J. Clin. Pathol."},{"issue":"6458","key":"10.1016\/j.intimp.2025.115406_bb0060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/367040a0","article-title":"A brain serine\/threonine protein kinase activated by Cdc42 and Rac1","volume":"367","author":"Manser","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115406_bb0065","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.gene.2016.12.014","article-title":"Structure, biochemistry, and biology of PAK kinases","volume":"605","author":"Kumar","year":"2017","journal-title":"Gene"},{"issue":"7","key":"10.1016\/j.intimp.2025.115406_bb0070","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S1357-2725(01)00158-3","article-title":"p21-activated kinases: three more join the Pak","volume":"34","author":"Jaffer","year":"2002","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115406_bb0075","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4161\/cl.21882","article-title":"PAK signaling in cancer","volume":"2","author":"Ye","year":"2012","journal-title":"Cell Logist."},{"issue":"3","key":"10.1016\/j.intimp.2025.115406_bb0080","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ijc.24428","article-title":"P21-activated kinase 5 is overexpressed during colorectal cancer progression and regulates colorectal carcinoma cell adhesion and migration","volume":"125","author":"Gong","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115406_bb0085","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/febs.12048","article-title":"A role for p21-activated kinase 7 in the development of gastric cancer","volume":"280","author":"Gu","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.intimp.2025.115406_bb0090","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s13277-013-0824-x","article-title":"PAK5-Egr1-MMP2 signaling controls the migration and invasion in breast cancer cell","volume":"34","author":"Wang","year":"2013","journal-title":"Tumour Biol."},{"key":"10.1016\/j.intimp.2025.115406_bb0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11010-013-1767-7","article-title":"The overexpression of P21-activated kinase 5 (PAK5) promotes paclitaxel-chemoresistance of epithelial ovarian cancer","volume":"383","author":"Li","year":"2013","journal-title":"Mol. Cell. Biochem."},{"issue":"9","key":"10.1016\/j.intimp.2025.115406_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.559","article-title":"PAK5-stabilized Smuc confers renal cell carcinoma metastasis","volume":"11","author":"Huo","year":"2021","journal-title":"Clin. Transl. Med."},{"issue":"6","key":"10.1016\/j.intimp.2025.115406_bb0105","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41418-018-0178-4","article-title":"PAK5 promotes the migration and invasion of cervical cancer cells by phosphorylating SATB1","volume":"26","author":"Huo","year":"2019","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.intimp.2025.115406_bb0110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/aps.2013.31","article-title":"P21-activated kinase 5 plays essential roles in the proliferation and tumorigenicity of human hepatocellular carcinoma","volume":"35","author":"Fang","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.intimp.2025.115406_bb0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbrc.2015.06.108","article-title":"miR-129 suppresses tumor cell growth and invasion by targeting PAK5 in hepatocellular carcinoma","volume":"464","author":"Zhai","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.intimp.2025.115406_bb0120","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/cbin.10351","article-title":"p21-activated kinase 7 is an oncogene in human osteosarcoma","volume":"38","author":"Han","year":"2014","journal-title":"Cell Biol. Int."},{"issue":"2","key":"10.1016\/j.intimp.2025.115406_bb0125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3233\/CBM-150557","article-title":"Over expression of p21-activated kinase 7 associates with lymph node metastasis in esophageal squamous cell cancers","volume":"16","author":"He","year":"2016","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.intimp.2025.115406_bb0130","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s13277-010-0071-3","article-title":"p21-activated kinase 5 inhibits camptothecin-induced apoptosis in colorectal carcinoma cells","volume":"31","author":"Wang","year":"2010","journal-title":"Tumour Biol."},{"issue":"13","key":"10.1016\/j.intimp.2025.115406_bb0135","article-title":"The predictive value of PAK7 mutation for immune checkpoint inhibitors therapy in non-small cell Cancer","volume":"3","author":"Zeng","year":"2022","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.intimp.2025.115406_bb0140","doi-asserted-by":"crossref","first-page":"6636","DOI":"10.1016\/j.bmcl.2013.10.051","article-title":"p21-activated kinase 5: a pleiotropic kinase","volume":"23","author":"Wen","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.intimp.2025.115406_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-017-0610-5","article-title":"PAK5-mediated phosphorylation and nuclear translocation of NF-\u03baB-p65 promotes breast cancer cell proliferation in vitro and in vivo[J]","volume":"36","author":"Zhang","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.115406_bb0150","first-page":"2202","article-title":"PAK5 overexpression is associated with lung metastasis in osteosarcoma","volume":"15","author":"Han","year":"2018","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.intimp.2025.115406_bb0155","article-title":"Pak5 induces emt and promotes cell migration and invasion by activating the PI3K\/Akt pathway in ovarian cancer[J]","volume":"2018","author":"Li","year":"2018","journal-title":"Anal. Cell. Pathol."},{"key":"10.1016\/j.intimp.2025.115406_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110803","article-title":"PAK5 potentiates slug transactivation of N-cadherin to facilitate metastasis of renal cell carcinoma","volume":"110","author":"Liu","year":"2023","journal-title":"Cell. Signal."},{"issue":"2","key":"10.1016\/j.intimp.2025.115406_bb0165","doi-asserted-by":"crossref","first-page":"230","DOI":"10.7150\/ijbs.9193","article-title":"Efficient inhibition of human glioma development by RNA interference-mediated silencing of PAK5","volume":"11","author":"Gu","year":"2015","journal-title":"Int. J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2025.115406_bb0170","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/jcb.22639","article-title":"p120-catenin is a binding partner and substrate for group B Pak kinases","volume":"110","author":"Wong","year":"2010","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.intimp.2025.115406_bb0175","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/jcb.21809","article-title":"p21 activated kinase 5 activates Raf-1 and targets it to mitochondria","volume":"105","author":"Wu","year":"2008","journal-title":"J. Cell. Biochem."},{"issue":"12","key":"10.1016\/j.intimp.2025.115406_bb0180","article-title":"Immunotherapy advances in locally advanced and recurrent\/metastatic head and neck squamous cell carcinoma and its relationship with human papillomavirus","volume":"8","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115406_bb0185","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14728214.2020.1852215","article-title":"Emerging immune checkpoint inhibitors for the treatment of head and neck cancers","volume":"25","author":"Green","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"9","key":"10.1016\/j.intimp.2025.115406_bb0190","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3390\/cells9092103","article-title":"HNSCC: tumour antigens and their targeting by immunotherapy","volume":"9","author":"von Witzleben","year":"2020","journal-title":"Cells"},{"issue":"555","key":"10.1016\/j.intimp.2025.115406_bb0195","article-title":"Immune checkpoint inhibitor resistance in hepatocellular carcinoma","volume":"28","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2025.115406_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist. Updat."},{"issue":"2","key":"10.1016\/j.intimp.2025.115406_bb0205","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/rco2.32","article-title":"Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans","volume":"4","author":"Castillo","year":"2021","journal-title":"JCSM Rapid Commun."},{"key":"10.1016\/j.intimp.2025.115406_bb0210","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","article-title":"DAMP-sensing receptors in sterileinflammation and inflammatory diseases","volume":"20","author":"Gong","year":"2020","journal-title":"Nat. Rev. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925013979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925013979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T07:54:23Z","timestamp":1758786863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925013979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":42,"alternative-id":["S1567576925013979"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115406","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role and mechanism of PAK5 in the development and immunotherapy of oral squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115406"}}